The <scp>PRIME</scp> trial: An investigator‐initiated, multicentre, phase <scp>II</scp> study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase ( IDH )‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

Rory M. Shallis, Jennifer VanOudenhove, Namrata Chandhok, Justin Watts, Deepa Jeyakumar, Daniel R. Reed, Jan Phillip Bewersdorf, Diane Durecki, Scott Boerner, Richard F. Little, Steven D. Gore, Jing Li, Xun Bao, Li Chen, Sayak Ghatak, Thomas Prebet, Ranjit S. Bindra, Amer M. Zeidan, Stephanie Halene

Open source

DOI: 10.1111/bjh.70756
Published: 2026-08-26
Container: British Journal of Haematology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/bjh.70756,
  title = {The
                    <scp>PRIME</scp>
                    trial: An investigator‐initiated, multicentre, phase
                    <scp>II</scp>
                    study of the poly(ADP‐ribose) polymerase inhibitor olaparib in
                    <i>isocitrate dehydrogenase</i>
                    (
                    <i>IDH</i>
                    )‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes},
  author = {Rory M. Shallis and Jennifer VanOudenhove and Namrata Chandhok and Justin Watts and Deepa Jeyakumar and Daniel R. Reed and Jan Phillip Bewersdorf and Diane Durecki and Scott Boerner and Richard F. Little and Steven D. Gore and Jing Li and Xun Bao and Li Chen and Sayak Ghatak and Thomas Prebet and Ranjit S. Bindra and Amer M. Zeidan and Stephanie Halene},
  year = {2026},
  journal = {British Journal of Haematology},
  doi = {10.1111/bjh.70756},
  url = {https://doi.org/10.1111/bjh.70756}
}

RIS

TY  - JOUR
TI  - The
                    <scp>PRIME</scp>
                    trial: An investigator‐initiated, multicentre, phase
                    <scp>II</scp>
                    study of the poly(ADP‐ribose) polymerase inhibitor olaparib in
                    <i>isocitrate dehydrogenase</i>
                    (
                    <i>IDH</i>
                    )‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes
AU  - Rory M. Shallis
AU  - Jennifer VanOudenhove
AU  - Namrata Chandhok
AU  - Justin Watts
AU  - Deepa Jeyakumar
AU  - Daniel R. Reed
AU  - Jan Phillip Bewersdorf
AU  - Diane Durecki
AU  - Scott Boerner
AU  - Richard F. Little
AU  - Steven D. Gore
AU  - Jing Li
AU  - Xun Bao
AU  - Li Chen
AU  - Sayak Ghatak
AU  - Thomas Prebet
AU  - Ranjit S. Bindra
AU  - Amer M. Zeidan
AU  - Stephanie Halene
PY  - 2026
JO  - British Journal of Haematology
DO  - 10.1111/bjh.70756
UR  - https://doi.org/10.1111/bjh.70756
ER  -

APA

Shallis, R. M., VanOudenhove, J., Chandhok, N., Watts, J., Jeyakumar, D., Reed, D. R., Bewersdorf, J. P., Durecki, D., Boerner, S., Little, R. F., Gore, S. D., Li, J., Bao, X., Chen, L., Ghatak, S., Prebet, T., Bindra, R. S., Zeidan, A. M., & Halene, S. (2026). The <scp>PRIME</scp> trial: An investigator‐initiated, multicentre, phase <scp>II</scp> study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase ( IDH )‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes. British Journal of Haematology. https://doi.org/10.1111/bjh.70756

Source records

crossref · retrieved 2026-09-27T06:38:40.037Z

The <scp>PRIME</scp> trial: An investigator‐initiated, multicentre, phase <scp>II</scp> study of the poly(ADP‐ribose) polymerase inhibitor olaparib in <i>isocitrate dehydrogenase</i> ( <i>IDH</i> )‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

Credibility signals

Cite this work

BibTeX

RIS

APA

Source records